A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2012-10-29
600
Participants Needed
16
Research Sites
N/A
Total Duration
On this page
AI-Summary
Official Title
Who Can Participate
Trial Site Locations
How is the study designed?
Frequently Asked Questions
Research Publications
AI-Summary
What this Trial Is About
To evaluate pyrimethamine as a prophylactic agent against toxoplasmic encephalitis in individuals who are coinfected with HIV and latent Toxoplasma gondii.
Toxoplasmic encephalitis is a major cause of illness and death in AIDS patients. Standard treatment for toxoplasmic encephalitis is to combine pyrimethamine and sulfadiazine. Continuous treatment is necessary to prevent recurrence of the disease, but constant use of pyrimethamine/sulfadiazine is associated with toxicity. Clindamycin has been shown to be effective in treatment of toxoplasmic encephalitis in animal studies. This study evaluates pyrimethamine as a preventive treatment against toxoplasmic encephalitis (per 3/26/91 amendment, clindamycin arm was discontinued).
CONDITIONS
Official Title
A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection
Who Can Participate
Age: 13Years +
All Genders
Eligibility Criteria
You may qualify if you...
Inclusion Criteria
Concurrent Medication:
Required:
Prophylactic treatment for Pneumocystis carinii pneumonia with aerosolized pentamidine, dapsone, or trimethoprim / sulfamethoxazole.
Allowed:
Most medications not specifically excluded.
Prior Medication:
Allowed:
Antivirals.
Antiretrovirals.
Patients:
Must be HIV positive or have an AIDS-defining illness OR be at known risk for HIV infection and have a CD4 cell count < 200/mm3 and no other known immunosuppressive disease.
Must have positive titer for Toxoplasma gondii.
Must be or become a patient of a CPCRA physician.
May participate in other clinical trials as long as there is no potential activity against Toxoplasma gondii or cross-toxicity among study drugs.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
History of ocular, pulmonary, or central nervous system (CNS) toxicity.
CNS lesions.
Neurologic deficits except peripheral neuropathy.
Mild, moderate, severe, or end-stage AIDS dementia complex. Grade 3 or higher nausea and/or vomiting.
Sensitivity to pyrimethamine.
Concurrent Medication:
Excluded:
On-going therapy with clindamycin, fansidar, methotrexate, trimetrexate, spiramycin, azithromycin, clarithromycin, 566C80, and/or sulfa agents other than anti-PCP agents.
Patients with the following are excluded:
History of ocular, pulmonary, or central nervous system (CNS) toxicity.
CNS lesions or history of CNS lesions.
Neurologic deficits except peripheral neuropathy.
Mild, moderate, severe, or end-stage AIDS dementia complex. Grade 3 or higher nausea and/or vomiting.
Sensitivity to pyrimethamine.
You will not qualify if you...
History of severe allergic reactions to study medication
Currently pregnant or breastfeeding
Recent participation in another clinical trial within the last 30 days
Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Total: 16 locations
1
Community Consortium of San Francisco
San Francisco, California, United States, 94110
Status Unknown
2
Denver CPCRA / Denver Public Hlth
Denver, Colorado, United States, 802044507
Status Unknown
3
Hill Health Corp
New Haven, Connecticut, United States, 06519
Status Unknown
4
Wilmington Hosp / Med Ctr of Delaware
Wilmington, Delaware, United States, 19899
Status Unknown
5
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States, 30308
Status Unknown
6
AIDS Research Alliance - Chicago
Chicago, Illinois, United States, 60657
Status Unknown
7
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med
New Orleans, Louisiana, United States, 70112
Status Unknown
8
Comprehensive AIDS Alliance of Detroit
Detroit, Michigan, United States, 48201
Status Unknown
9
Henry Ford Hosp
Detroit, Michigan, United States, 48202
Status Unknown
10
North Jersey Community Research Initiative
Newark, New Jersey, United States, 071032842
Status Unknown
11
Addiction Research and Treatment Corp
Brooklyn, New York, United States, 11201
Status Unknown
12
Clinical Directors Network of Region II
New York, New York, United States, 10011
Status Unknown
13
Harlem AIDS Treatment Group / Harlem Hosp Ctr
New York, New York, United States, 10037
Status Unknown
14
Bronx Lebanon Hosp Ctr
The Bronx, New York, United States, 10456
Status Unknown
15
Portland Veterans Adm Med Ctr / Rsch & Education Grp
Portland, Oregon, United States, 972109951
Status Unknown
16
Richmond AIDS Consortium
Richmond, Virginia, United States, 23298
Status Unknown
Loading map...
How is the study designed?
Study Type
INTERVENTIONAL
Masking
N/A
Allocation
N/A
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Clinical programs for clinical research on AIDS: description of a randomized prospective study of clindamycin versus pyrimethamine for prevention of Toxoplasma gondii infection.
Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS.